Inventiva S.A. Revenue 2011-2026 | IVA

Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.

Traditionally defined as follows:
Revenue = Price * Quantity of products

Revenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.^[1]

This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.

Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.

Annual Revenue Inventiva S.A.

2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
9.2 M	17.5 M	12.2 M	4.19 M	372 K	7 M	3.2 M	6.52 M	9.45 M	4.87 M	3.28 M	3.06 M	-	-

All numbers in EUR currency

Indicator range from annual reports

Maximum	Minimum	Average
17.5 M	372 K	6.73 M

References

Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).

Revenue of other stocks in the Biotechnology industry

Issuer	Revenue	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	238 M	-	2.43 %	$ 254 M	Germany
Adagene ADAG	10.2 M	$ 2.19	7.88 %	$ 123 M	China
Acorda Therapeutics ACOR	118 M	-	-24.86 %	$ 820 K	USA
BioLineRx Ltd. BLRX	28.9 M	$ 3.03	2.35 %	$ 908 M	Israel
BioNTech SE BNTX	482 M	$ 117.93	-0.46 %	$ 27.2 B	Germany
Aeterna Zentaris AEZS	9.59 M	-	5.93 %	$ 314 M	Canada
Alterity Therapeutics Limited ATHE	109 K	$ 3.31	1.22 %	$ 7.96 B	Australia
BioXcel Therapeutics BTAI	2.27 M	$ 1.83	0.83 %	$ 4.64 M	USA
AgeX Therapeutics AGE	142 K	-	-10.17 %	$ 12.2 K	USA
Burford Capital Limited BUR	330 M	$ 9.64	-2.33 %	$ 1.58 B	Britain
Alexion Pharmaceuticals, Inc. ALXN	6.07 B	-	-	$ 40.3 B	USA
Can-Fite BioPharma Ltd. CANF	853 K	$ 4.23	1.68 %	$ 9.2 B	Israel
Aeglea BioTherapeutics AGLE	886 K	-	-	$ 1.01 B	USA
Amphastar Pharmaceuticals AMPH	732 M	$ 26.09	-0.21 %	$ 1.26 B	USA
Midatech Pharma plc MTP	381 K	-	-18.52 %	$ 27.3 M	Britain
EyeGate Pharmaceuticals, Inc. EYEG	12.1 K	-	-1.52 %	$ 24.7 M	USA
Coherus BioSciences CHRS	257 M	$ 2.03	27.67 %	$ 191 M	USA
Aravive ARAV	9.14 M	-	-13.39 %	$ 1.45 M	USA
Институт стволовых клеток человека ISKJ	1.08 B	-	-	-	Russia
Ascendis Pharma A/S ASND	364 M	$ 230.76	0.92 %	$ 5 B	Danmark
Aytu BioScience AYTU	66.4 M	$ 2.72	0.37 %	$ 17.1 M	USA
Corcept Therapeutics Incorporated CORT	675 M	$ 42.02	1.74 %	$ 4.34 B	USA
Acasti Pharma ACST	100 M	-	4.01 %	$ 150 M	Canada
Catalyst Pharmaceuticals CPRX	492 M	$ 24.23	-0.9 %	$ 2.87 B	USA
Arrowhead Pharmaceuticals ARWR	829 M	$ 70.82	1.77 %	$ 9.47 B	USA
Brickell Biotech BBI	8.01 M	-	-5.38 %	$ 6.06 M	USA
BeiGene, Ltd. BGNE	3.81 B	-	0.49 %	$ 251 B	Cayman-islands
Champions Oncology CSBR	56.9 M	$ 6.9	-0.43 %	$ 94.3 M	USA
Ayala Pharmaceuticals AYLA	692 K	-	-	$ 7.46 M	Israel
Adaptimmune Therapeutics plc ADAP	60.3 M	-	-15.15 %	$ 60.3 M	Britain
AIkido Pharma AIKI	18.1 M	-	1.93 %	$ 17.4 M	USA
Albireo Pharma ALBO	40.6 M	-	-0.23 %	$ 916 M	USA
CureVac N.V. CVAC	48.9 M	-	-	$ 867 M	Germany
Acer Therapeutics ACER	1.26 M	-	2.71 %	$ 14 M	USA
Bellicum Pharmaceuticals BLCM	1.5 M	-	-9.72 %	$ 5.89 M	USA
Alpine Immune Sciences ALPN	30.1 M	-	-	$ 2.17 B	USA
AlloVir ALVR	165 K	-	4.14 %	$ 49.1 M	USA
Ampio Pharmaceuticals AMPE	1.16 M	-	-11.43 %	$ 502 K	USA
Biogen BIIB	9.68 B	$ 171.66	-1.23 %	$ 25 B	USA
Bio-Path Holdings BPTH	37 K	-	-	$ 100 K	USA
Baudax Bio BXRX	1.27 M	-	0.59 %	$ 63 K	USA